Matthew W. Hagen

Matthew W. Hagen

Auto-generated profile, based on publicly available information

Matthew W. Hagen

Fred Hutchinson Cancer Center

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 January 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
JDJustin M. Dean
Justin M. Dean
EMEvelyn McClendon
Evelyn McClendon
KHKelly Hansen
Kelly Hansen
AAAryan Azimi-Zonooz
Aryan Azimi-Zonooz
KCKevin Chen
Kevin Chen
SBStephen A. Back
Stephen A. Back
Preterm ischemia disrupts MRI-defined maturation of the cerebral cortex by impairing the differentiation of cortical neurons in fetal lambs.

1 April 2019 in Arteriosclerosis, Thrombosis, and Vascular Biology
Verified
Journal Article
Closed access
PDF file
CLChristina U. Lorentz
Christina U. Lorentz
NVNorah G. Verbout
Norah G. Verbout
MWMichael Wallisch
Michael Wallisch
MHMatthew W. Hagen
Matthew W. Hagen
JSJoseph J. Shatzel
Joseph J. Shatzel
ETErik I. Tucker
Erik I. Tucker
Objective—: Factor XI (FXI) contributes to thrombotic disease while playing a limited role in normal hemostasis. We generated a unique, humanized anti-FXI antibody, AB023, which blocks factor XIIa-mediated FXI activation without inhibiting FXI activation by thrombin or the procoagulant function of FXIa. We sought to confirm the antithrombotic activity of AB023 in a baboon thrombosis model and to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy adult subjects. Approach and Results—: In a primate model of acute vascular graft thrombosis, AB023 reduced platelet and fibrin accumulation within the grafts by >75%. To evaluate the safety of AB023, we performed a first-in-human study in healthy adult volunteers without any serious adverse events. Overall, 10 of 21 (48%) subjects experienced 20 treatment-emergent adverse events, with 7 of 16 (44%) subjects following active treatment and 3 of 5 (60%) subjects following placebo. AB023 did not increase bleeding or prothrombin times. Anticoagulation was verified by a saturable ≈2-fold prolongation of the partial thromboplastin time for over 1 month after the highest dose. Conclusions—: AB023, which inhibits contact activation-initiated blood coagulation in vitro and experimental thrombus formation in primates, produced a dose-dependent duration of limited anticoagulation without drug-related adverse effects in a phase 1 trial. When put in context with earlier observations suggesting that FXI contributes to venous thromboembolism and cardiovascular disease, although contributing minimally to hemostasis, our data further justify clinical evaluation of AB023 in conditions where contact-initiated FXI activation is suspected to have a pathogenic role. Clinical Trial Registration—: URL: http://www.clinicaltrials.gov . Unique identifier: NCT03097341.

31 October 2016 in Journal of NeuroInterventional Surgery
Verified
Journal Article
Open access
PDF file
MHMatthew W Hagen
Matthew W Hagen
GGGaurav Girdhar
Gaurav Girdhar
JWJohn Wainwright
John Wainwright
MHMonica T Hinds
Monica T Hinds
Background Flow diverters offer a promising treatment for cerebral aneurysms. However, they have associated thromboembolic risks, mandating chronic dual antiplatelet therapy (DAPT). Shield Technology is a phosphorylcholine surface modification of the Pipeline Embolization Device (PED) flow diverter, which has shown significant reductions in material thrombogenicity in vitro. Objective To compare the thrombogenicity of PED, PED with Shield Technology (PED+Shield), and the Flow-Redirection Endoluminal Device (FRED)—with and without single antiplatelet therapy and DAPT—under physiological flow. Methods An established non-human primate ex vivo arteriovenous shunt model of stent thrombosis was used. PED, PED+Shield, and FRED were tested without antiplatelet therapy, with acetylsalicylic acid (ASA) monotherapy, and with DAPT. Radiolabeled platelet deposition was quantified over 1 hour for each device and total fibrin deposition was also quantified. Results Cumulative statistical analysis showed significantly lower platelet deposition on PED compared with FRED. The same statistical model showed significant decreases in platelet deposition when ASA, clopidogrel, or Shield Technology was used. Direct comparisons of device performances within antiplatelet conditions showed consistent significant decreases in platelet accumulation on PED+Shield relative to FRED. PED+Shield showed significant reductions in platelet deposition compared with unmodified PED without antiplatelet therapy and with DAPT. PED accumulated minimal fibrin with and without Shield Technology. Conclusions In this preclinical model, we have shown that the Shield Technology phosphorylcholine modification reduces the platelet-specific thrombogenicity of a flow diverter under physiologically relevant flow with and without DAPT. We have further identified increased fibrin-driven thrombogenicity associated with FRED relative to PED.

3 January 2014 in Annals of Neurology
Verified
Journal Article
Closed access
PDF file
EMEvelyn McClendon
Evelyn McClendon
KCKevin Chen
Kevin Chen
XGXi Gong
Xi Gong
ESElica Sharifnia
Elica Sharifnia
MHMatthew Hagen
Matthew Hagen
SBStephen A. Back
Stephen A. Back

16 April 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
TSTaasin Srivastava
Taasin Srivastava
PDParham Diba
Parham Diba
JDJustin M. Dean
Justin M. Dean
FBFatima Banine
Fatima Banine
DSDaniel Shaver
Daniel Shaver
SBStephen A. Back
Stephen A. Back
Cerebral white matter injury (WMI) persistently disrupts myelin regeneration by oligodendrocyte progenitor cells (OPCs). We identified a specific bioactive hyaluronan fragment (bHAf) that downregulates myelin gene expression and chronically blocks OPC maturation and myelination via a tolerance-like mechanism that dysregulates pro-myelination signaling via AKT. Desensitization of AKT occurs via TLR4 but not TLR2 or CD44. OPC differentiation was selectively blocked by bHAf in a maturation-dependent fashion at the late OPC (preOL) stage by a noncanonical TLR4/TRIF pathway that induced persistent activation of the FoxO3 transcription factor downstream of AKT. Activated FoxO3 selectively localized to oligodendrocyte lineage cells in white matter lesions from human preterm neonates and adults with multiple sclerosis. FoxO3 constraint of OPC maturation was bHAf dependent, and involved interactions at the FoxO3 and MBP promoters with the chromatin remodeling factor Brg1 and the transcription factor Olig2, which regulate OPC differentiation. WMI has adapted an immune tolerance–like mechanism whereby persistent engagement of TLR4 by bHAf promotes an OPC niche at the expense of myelination by engaging a FoxO3 signaling pathway that chronically constrains OPC differentiation.

1 March 2019 in Acta Biomaterialia
Verified
Journal Article
Closed access
DADeirdre Anderson
Deirdre Anderson
KTKatie P. Truong
Katie P. Truong
MHMatthew W. Hagen
Matthew W. Hagen
EYEvelyn K.F. Yim
Evelyn K.F. Yim
MHMonica T. Hinds
Monica T. Hinds